| Class | Sedative |
|---|---|
| Chemistry |
Benzodiazepine |
| Routes of administration |
IV, IM, subcutaneously, intranasally buccaly and orally (though the oral dose required is about doubled) |
| Absorption |
44% bioavauilability; well absorbed, but also undergoes significant first-pass metabolism |
| Solubility |
pKa 6.7; good water solubility at pH <4 (as a hydrochloride salt) -0 when injected, it becomes lipid-soluble at physiologic pH |
| Distribution |
VOD = 0.8 to 1.5 L/kg; 96% protein bound |
| Metabolism |
Hepatic metabolism to α-hydroxymidazolam (which is active), and then an inactive renally excreted glucouronide. α-hydroxymidazolam can accumulate in renal failure |
| Elimination |
Both the active metabolite and the inactive glucouronide are renally excreted |
| Time course of action |
Redistribution half-life is 15 minutes; elimination half-life is 1.5-3.5 hours |
| Target receptor |
GABA-A channel (a separate binding site from GABA) |
| Mechanism of action |
Allosteric modulator of the GABA-A receptor: acts on GABA-A chloride channels, where it binds to a site distinct from the GABA binding site, and potentiates the effects of GABA, this increasing the chloride current and hyperpolarising the cell membrane of the neuron |
| Clinical effects |
Sedation, amnesia, anticonvulsant effect, mild decrease in cerebral oxygen demand, no effect on ICP. |
| Literature reference |
Okkola & Ahonen (2008) |
| CICM details of understanding | Level 1 |
| Mentioned around Deranged Physiology | |
| Related SAQs |
Question 1 from the second paper of 2022 (midazolam alone) Question 9 from the second paper of 2019 (propofol vs midazolam) Question 7 from the first paper of 2019 (midazolam vs. dexmedetomidine) Question 4 from the second paper of 2018 (ketamine vs midazolam) Question 24 from the first paper of 2016 (midazolam vs. the “ideal” agent) |